Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Nov;18(2):123–125. doi: 10.1007/BF00205746

Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide

J Bubeník 1, J Ježek 2, M Zaoral 2, J Hofmann 1, Y V Gruntenko 3, J G Osipov 3, A G Zolotareva 3, T E Vakhrusheva 3, V G Budker 4
PMCID: PMC11039113  PMID: 6568871

Abstract

Treatment with synthetic MDP inhibited growth of transplantable, chemically induced tumors in syngeneic mice. The tumor-inhibitory effect was dependent on the schedule of MDP administration.

Growth of SC transplants of a nonmetastasizing, MC-induced fibrosarcoma, MC11, was inhibited by local treatment with 200 μg and 1,000 μg MDP given SC 5–7 weeks before challenge. Treatment with lower (10 μg and 100 μg) doses of MDP and shorter (1–4 weeks) time intervals was not effective. Single doses of MDP (10–1,000 μg) 1–3 weeks after challenge had no effect.

Growth of IV-inoculated, metastasizing AAT-induced hepatoma A was inhibited by IV injections of 20 μg MDP given 1 and 2 days prior to the challenge. Significant increases in the survival of hepatoma-bearing mice were observed only after injections of MDP incorporated in multilamellar liposomes.

Keywords: Tumor Growth, Cancer Research, Single Dose, Dipeptide, Local Treatment

Abbreviations

MDP

n-acetylmuramyl-l-alanyl-d-isoglutamine

B10

C57BL/10ScSnPh mice

MC

3-methylcholanthrene

ATT

o-amino-azotoluene

PBS

phosphate-buffered saline

References

  • 1.Azuma I, Sugimura IK, Taniyama T, Yamawaki M, Yamamura Y, Kusumoto S, Okada S, Shiba T. Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds. Infect Immun. 1976;14:18–27. doi: 10.1128/iai.14.1.18-27.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Azuma I, Yamawaki M, Uemiya M, Saiki I, Tanio Y, Kobayashi S, Fukuda T, Imada I, Yamamura Y. Adjuvant and antitumour activities of quinonyl-N-acetylmuramyl-dipeptides. Gann. 1979;70:847–848. [PubMed] [Google Scholar]
  • 3.Baldwin RW, Pimm MV. BCG in tumour immunotherapy. Adv Cancer Res. 1978;28:91–149. doi: 10.1016/s0065-230x(08)60647-8. [DOI] [PubMed] [Google Scholar]
  • 4.Bubeník J, Koldovský P. Factors influencing the induction of enhancement and resistance to methylcholanthrene-induced tumours in a syngeneic system. Folia Biol. 1965;11:258–264. [PubMed] [Google Scholar]
  • 5.Bubeník J, Indrová M, Němečková Š, Malkovský M, Von Broen B, Pálek V, Anderlíková J. Solubilized tumour-asociated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. Int J Cancer. 1978;21:348–355. doi: 10.1002/ijc.2910210316. [DOI] [PubMed] [Google Scholar]
  • 6.Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974;59:1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  • 7.Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680–1684. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kaledin VI, Matienko NA, Nikolin VP, Gruntenko YV, Budker VG. Intralymphatic administration of liposome-encapsulated drugs to mice: possibility for suppression of the growth of tumor metastases in the lymph nodes. JNCI. 1981;66:881–887. [PubMed] [Google Scholar]
  • 9.Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. JNCI. 1982;69:1189–1198. [PubMed] [Google Scholar]
  • 10.Kotani S, Takada H, Tsujimoto M, Kubo T, Ogawa T, Azuma I, Ogawa H, Matsumoto K, Siddiqui WA, Tanaka A, Nagao S, Kohashi O, Kanoh S, Shiba T, Kusumoto S. Non-specific and antigen-specific stimulation of host defence mechanisms by lipophilic derivatives of muramyl dipeptides. In: Jeljawzewicz J, Pulverer G, Roszkowski W, editors. Bacteria and cancer. London: Academic Press; 1982. pp. 67–107. [Google Scholar]
  • 11.Leclerc C, Lamensans A, Chedid L, Drapier JC, Petit JF, Wietzerbin J, Lederer E. Nonspecific immunoprevention of L 1210 leukemia by cord factor 6-6′ dimycolate of trehalose, administered in a metabolizable oil. Cancer Immunol Immunother. 1976;1:227–233. [Google Scholar]
  • 12.Lederer E. Combined immunostimulation with synthetic muramyl dipeptide (MDP) and natural and synthetic trehalose diesters. In: Israël L, Lagrange P, Salomon JC, editors. Cancer immunology and parasite immunology. Paris: INSERM; 1980. pp. 137–145. [Google Scholar]
  • 13.Lederer E, Chedid L. Immunomodulation by synthetic muramyl peptides and trehalose diesters. In: Mihich E, editor. Immunological approaches to cancer therapeutics. New York: Wiley Interscience; 1982. pp. 107–135. [Google Scholar]
  • 14.Lefrancier P, Choay J, Derrien M, Lederman I. Synthesis of N-acetylmuramyl-l-alanyl-d-isoglutamine, an adjuvant of the immune response and some N-acetylmuramyl-peptide analogs. Int J Peptide Protein Res. 1977;9:249–257. doi: 10.1111/j.1399-3011.1977.tb03488.x. [DOI] [PubMed] [Google Scholar]
  • 15.McLaughlin CA, Schwärtzman SM, Horner BL, Jones GH, Moffat JG, Nestor JJ, Tegg D. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. Science. 1980;208:415–416. doi: 10.1126/science.7189295. [DOI] [PubMed] [Google Scholar]
  • 16.Merser C, Sinay P, Adam A. Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1975;66:1316–1322. doi: 10.1016/0006-291x(75)90503-3. [DOI] [PubMed] [Google Scholar]
  • 17.Oppenheim JJ, Togawa A, Chedid L, Mizel S. Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol. 1980;50:71–81. doi: 10.1016/0008-8749(80)90007-6. [DOI] [PubMed] [Google Scholar]
  • 18.Philips NC, Paraf A, Bahr GM, Chedid L. Modulation of murine lymphoma growth by MDP, MDP(D-D) and cyclophosphamide. 1. Inhibition of growth in vivo. Int J Immunopharmacol. 1983;5:219–227. doi: 10.1016/0192-0561(83)90059-0. [DOI] [PubMed] [Google Scholar]
  • 19.Sharma SD, Tsai V, Krahenbuhl JL, Remington JS. Augmentation of mouse natural killer cell activity by muramyl dipeptide and its analogs. Cell Immunol. 1981;62:101–109. doi: 10.1016/0008-8749(81)90303-8. [DOI] [PubMed] [Google Scholar]
  • 20.Yamamura Y, Azuma I, Sugimura K, Yamawaki M, Uemiya M, Kusumoto S, Okada S, Shiba T. Immunological and anti-tumor activities of synthetic 6-0-mycoloyl-N-acetylmuramyl dipeptides. Proc Jpn Acad. 1977;53:63–66. [Google Scholar]
  • 21.Yarkoni E, Lederer E, Rapp HJ. Immunotherapy of experimental cancer with a mixture of synthetic muramyl dipeptide and trehalose dimycolate. Infect Immun. 1981;32:273–276. doi: 10.1128/iai.32.1.273-276.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zaoral M, Ježek J, Straka R, Mašek K. Glycopeptides of bacterial walls. A novel method of removal benzyl and benzylidene residues. Collect Czech Chem Commun. 1978;43:1797–1802. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES